Search results - Portal of Medical Data Models (MDM-Portal)

Filter search results

Keywords

Asthma ×

Show more Keywords

Table of contents

Select data models

Selected data models

You must log in to select data models for download or further analysis.

483 Search results.

A Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of CAT-354 - Eligibility

- 9/20/21 - 1 form, 2 itemgroups, 27 items, 2 languages

Itemgroups: Inclusion Criteria,Exclusion Criteria

ODM derived from http://clinicaltrials.gov/show/NCT00640016

GSK Influence of PPAR gamma agonist vs. Placebo on allergen-induced late asthmatic response NCT00318630 - Laboratory Examination - Treatment Period 2, Day 28, Pre-dose

- 4/29/22 - 1 form, 6 itemgroups, 47 items, 1 language

Itemgroups: Pregnancy Test,Drug Screen,Alcohol breath test,Carbon Monoxide test,Haematology,Clinical Chemistry

Study ID: 104385 Clinical Study ID: RES104385 Study Title: A randomised double-blind two-period crossover study to investigate the effect of treatment with repeat doses of a PPAR gamma agonist on the allergen-induced late asthmatic response in subjects with mild asthma compared with repeat doses of placebo Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00318630 https://clinicaltrials.gov/ct2/show/NCT00318630 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: rosiglitazone Trade Name: Avandia XR,Avandia; Rosiglitazone XR,Avandia XR,Avandia Study Indication: Asthma This ODM-file contains Laboratory Examinations: Pregnancy test, Drug screen, alcohol breath test, carbon monoxide test, haematology and clinical chemistry. Time: Treatment Period 2, Day 28, Pre-dose.

GSK Influence of PPAR gamma agonist vs. Placebo on allergen-induced late asthmatic response NCT00318630 - Unscheduled Laboratory Results

- 4/13/22 - 1 form, 3 itemgroups, 55 items, 2 languages

Itemgroups: Laboratory result data - Haematology,Laboratory result data - Clinical chemistry,Urinalysis

Study ID: 104385 Clinical Study ID: RES104385 Study Title: A randomised double-blind two-period crossover study to investigate the effect of treatment with repeat doses of a PPAR gamma agonist on the allergen-induced late asthmatic response in subjects with mild asthma compared with repeat doses of placebo Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00318630 https://clinicaltrials.gov/ct2/show/NCT00318630 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: rosiglitazone Trade Name: Avandia XR,Avandia; Rosiglitazone XR,Avandia XR,Avandia Study Indication: Asthma This ODM-file contains Unscheduled Laboratory Results (Haematology, clinical chemistry, Urinalysis).

GSK Influence of PPAR gamma agonist vs. Placebo on allergen-induced late asthmatic response NCT00318630 - Laboratory Examination - Treatment Period 2, Day 1, Pre-dose

- 4/13/22 - 1 form, 6 itemgroups, 47 items, 2 languages

Itemgroups: Pregnancy Test,Drug Screen,Alcohol breath test,Carbon Monoxide test,Haematology,Clinical Chemistry

Study ID: 104385 Clinical Study ID: RES104385 Study Title: A randomised double-blind two-period crossover study to investigate the effect of treatment with repeat doses of a PPAR gamma agonist on the allergen-induced late asthmatic response in subjects with mild asthma compared with repeat doses of placebo Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00318630 https://clinicaltrials.gov/ct2/show/NCT00318630 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: rosiglitazone Trade Name: Avandia XR,Avandia; Rosiglitazone XR,Avandia XR,Avandia Study Indication: Asthma This ODM-file contains Laboratory Examinations: Pregnancy test, Drug screen, alcohol breath test, carbon monoxide test, haematology and clinical chemistry. Time: Treatment Period 2, Day 1, Pre-Dose.

GSK Influence of PPAR gamma agonist vs. Placebo on allergen-induced late asthmatic response NCT00318630 - Laboratory Examination - Treatment Period 2, Day 14, Pre-dose

- 4/6/22 - 1 form, 3 itemgroups, 35 items, 1 language

Itemgroups: Pregnancy Test,Haematology,Clinical Chemistry

Study ID: 104385 Clinical Study ID: RES104385 Study Title: A randomised double-blind two-period crossover study to investigate the effect of treatment with repeat doses of a PPAR gamma agonist on the allergen-induced late asthmatic response in subjects with mild asthma compared with repeat doses of placebo Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00318630 https://clinicaltrials.gov/ct2/show/NCT00318630 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: rosiglitazone Trade Name: Avandia XR,Avandia; Rosiglitazone XR,Avandia XR,Avandia Study Indication: Asthma This ODM-file contains Laboratory Examinations: Pregnancy test, Drug screen, alcohol breath test, carbon monoxide test, haematology and clinical chemistry. Time: Treatment Period 2, Day 14, Pre-dose.

Eligibility Asthma NCT00384813

- 9/27/21 - 1 form, 2 itemgroups, 10 items, 1 language

Itemgroups: Inclusion Criteria,Exclusion Criteria

Family-Focused, Stress-Reduction Program to Improve the Health Care of Urban Children With Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT00384813

Eligibility Asthma NCT02245672

- 9/27/21 - 1 form, 1 itemgroup, 18 items, 1 language

Itemgroup: Criteria

MGR001 / Advair Diskus Local Equivalence Study in Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT02245672

Eligibility Asthma NCT02230332

- 9/27/21 - 1 form, 2 itemgroups, 15 items, 1 language

Itemgroups: Inclusion Criteria,Exclusion Criteria

Alendronate to Prevent Loss of Bronchoprotection in Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT02230332

Eligibility Asthma NCT00320034

- 9/27/21 - 1 form, 2 itemgroups, 15 items, 1 language

Itemgroups: Inclusion Criteria,Exclusion Criteria

Evaluation of the Effect of Levalbuterol on Allergen Induced Airway Inflammation In Subjects With Atopic Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT00320034

GSK Influence of PPAR gamma agonist vs. Placebo on allergen-induced late asthmatic response NCT00318630 - Screening Part 3 - Alcohol, Drugs, Tobacco and Laboratory Results

- 9/27/21 - 1 form, 4 itemgroups, 77 items, 1 language

Itemgroups: Alcohol, drugs and tobacco,Laboratory result data - Haematology,Laboratory result data - Clinical chemistry,Urinalysis

Study ID: 104385 Clinical Study ID: RES104385 Study Title: A randomised double-blind two-period crossover study to investigate the effect of treatment with repeat doses of a PPAR gamma agonist on the allergen-induced late asthmatic response in subjects with mild asthma compared with repeat doses of placebo Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00318630 https://clinicaltrials.gov/ct2/show/NCT00318630 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: rosiglitazone Trade Name: Avandia XR,Avandia; Rosiglitazone XR,Avandia XR,Avandia Study Indication: Asthma This ODM-file contains Screening Part 3 - Alcohol, Drugs, Tobacco and Laboratory Results.

Effect of inhaled fluticasone furoate/Vilanterol combination on electrocardiographic parameters in healthy subjects, NCT01209026 - Eligibility criteria

- 9/27/21 - 1 form, 5 itemgroups, 43 items, 1 language

Itemgroups: Administrative data,Eligibility criteria,Inclusion criteria,Inclusion criteria for female,Exclusion criteria

Study ID: 102936 Clinical Study ID: HZA102936 Study Title:A randomised, placebo-controlled, four-way crossover repeat dose study to evaluate the effect of the inhaled fluticasone furoate (FF)/GW642444M combination on electrocardiographic parameters, with moxifloxacin as a positive control, in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01209026 https://clinicaltrials.gov/ct2/show/NCT01209026?term=NCT01209026 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: fluticasone furoate Trade Name: Allermist,Veramyst,Avamys; Veramyst,Avamys,Allermist Study Indication: Asthma The study consists of a screening, 8 treatment periods and a follow up. Treatment periods 1-4 are each 7 days long. Treatment period 1 Days 1-6 (TP1D-D6) Treatment period 1 Day 7 (TP1D7) Treatment period 2 Days 1-6 (TP2D1-D6) Treatment period 2 Day 7 (TP2D7) Treatment period 3 Days 1-6 (TP3D1-D6) Treatment period 3 Day 7 (TP3D7) Treatment period 4 Days 1-6 (TP4D1-D6) Treatment period 4 Day 7 (TP4D7) This document contains the eligibility criteria. It has to be filled in for screening.

GSK Influence of PPAR gamma agonist vs. Placebo on allergen-induced late asthmatic response NCT00318630 - Screening Part 5 - Pulmonary function: Methacholine and Asthma-allergen challenge

- 9/27/21 - 1 form, 8 itemgroups, 41 items, 1 language

Itemgroups: Pulmonary function tests: Pre-Methacholine Challenge,Pulmonary function tests: Methacholine Challenge,Pulmonary function tests: Post-Methacholine Challenge,PC20 (Methacholine Challenge),Skin Prick Test,Pulmonary function tests: pre-asthma-allergen challenge,Pulmonary function tests: asthma-allergen Challenge,Pulmonary function tests: Post-asthma-allergen Challenge

Study ID: 104385 Clinical Study ID: RES104385 Study Title: A randomised double-blind two-period crossover study to investigate the effect of treatment with repeat doses of a PPAR gamma agonist on the allergen-induced late asthmatic response in subjects with mild asthma compared with repeat doses of placebo Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00318630 https://clinicaltrials.gov/ct2/show/NCT00318630 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: rosiglitazone Trade Name: Avandia XR,Avandia; Rosiglitazone XR,Avandia XR,Avandia Study Indication: Asthma This ODM-file contains Screening Part 5 - Pulmonary function: Methacholine and Asthma-allergen challenge.

Please use this form for feedback, questions and suggestions for improvements.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.